In a landmark decision, the Supreme Court unanimously ruled in favor of the FDA’s approval of mifepristone, a medication used for medication abortion and miscarriage management. The conservative majority found that a group of antiabortion physicians did not have the standing to challenge the FDA’s decision, as they are not directly involved in prescribing, selling or manufacturing the drug.
Justice Brett M. Kavanaugh wrote the opinion for the court, stating that the plaintiffs did not suffer direct monetary injuries as a result of the FDA’s decisions to loosen regulations for obtaining mifepristone in 2016 and 2021. The American College of Obstetricians and Gynecologists celebrated the ruling, highlighting the decades of clinical research that have shown mifepristone to be safe and effective for patients.
The decision by the Supreme Court reinforces the importance of ensuring access to mifepristone for individuals seeking medication abortion or miscarriage management. It upholds the FDA’s actions in making the drug more readily available and affirms its safety and efficacy. Patients and clinicians can continue to rely on this medication for their reproductive health needs.
